Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
J Neurogastroenterol Motil. 2010 Jan;16(1):71-6. doi: 10.5056/jnm.2010.16.1.71. Epub 2010 Jan 31.
Cholecystokinin (CCK) belongs to a group of endogenous molecules known as brain-gut neuropeptides and functions as a neuropeptide as well as a gut hormone. It remains unclear whether genetic variation of the CCK receptor plays a role in irritable bowel syndrome (IBS). The aim of this study was to determine and compare the allele and genotype frequencies of the CCK(1) receptor polymorphisms between healthy controls and patients with IBS.
Genotyping of 80 patients with IBS (who met the Rome III criteria) and 76 healthy controls was performed. We performed PCR amplification for the CCK(1) receptor intron 1 779 T > C and Exon 1 G > A. We confirmed polymorphisms by direct sequencing method.
There was a significantly different trend for genotypic distributions of the CCK(1) receptor polymorphism between patients with IBS and healthy controls (p for trend = 0.048). The CCK(1) receptor intron 1 779 T >C polymorphic type was more common in patients with 'IBS-constipation predominant (IBS-C) and IBS-mixed (IBS-M) forms' (19/31, 61.3%) than healthy controls 32/76, 42.1% adjusted odd ratio 2.43, 95% Confidence interval 1.01-5.86). The genotypic distributions of the CCK(1) receptor exon 1 polymorphism were not significantly different between the two groups (p for trend = 0.223).
CCK(1) receptor polymorphisms were associated with IBS. In particular, the CCK(1) receptor intron 1 779 T > C polymorphic type was associated with 'IBS-C and IBS-M'. Further studies are needed in larger number of patients with an even distribution of IBS subtypes.
胆囊收缩素(CCK)属于一组内源性分子,称为脑-肠神经肽,作为神经肽和胃肠激素发挥作用。其遗传变异是否在肠易激综合征(IBS)中起作用尚不清楚。本研究旨在确定并比较健康对照组和 IBS 患者的 CCK(1)受体多态性的等位基因和基因型频率。
对 80 例符合 Rome III 标准的 IBS 患者(IBS 组)和 76 名健康对照者进行基因分型。我们对 CCK(1)受体内含子 1 779T > C 和外显子 1G > A 进行了 PCR 扩增。我们通过直接测序法证实了多态性。
IBS 患者和健康对照组之间 CCK(1)受体多态性的基因型分布存在显著不同的趋势(趋势检验 p=0.048)。CCK(1)受体内含子 1 779T > C 多态性在 IBS-便秘为主型(IBS-C)和 IBS-混合型(IBS-M)患者(19/31,61.3%)中比健康对照组(32/76,42.1%)更为常见,调整后的比值比为 2.43,95%置信区间为 1.01-5.86)。两组间 CCK(1)受体外显子 1 多态性的基因型分布无显著性差异(趋势检验 p=0.223)。
CCK(1)受体多态性与 IBS 相关。特别是 CCK(1)受体内含子 1 779T > C 多态性与“IBS-C 和 IBS-M”相关。需要在 IBS 亚型分布更为均匀的更大患者群体中进行进一步的研究。